stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) EPS (diluted)
Neurocrine Biosciences, Inc.'s EPS (diluted) for fiscal 2025 was $4.67, up 41.9% from $3.29 in fiscal 2024. Over the twelve months to 30 September 2026 it was $6.74. Over the past ten years it has ranged from −$1.63 (fiscal 2016) to $4.67 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 4 consecutive fiscal years. Neurocrine Biosciences, Inc. ranks 2nd of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $4.67 | 41.95% |
| FY2024 | $3.29 | 33.20% |
| FY2023 | $2.47 | 58.33% |
| FY2022 | $1.56 | 69.57% |
| FY2021 | $0.92 | (77.88%) |
| FY2020 | $4.16 | 966.67% |
| FY2019 | $0.39 | 77.27% |
| FY2018 | $0.22 | — |
| FY2017 | −$1.62 | — |
| FY2016 | −$1.63 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.96 | 41.22% |
| Jun 2026 | $1.39 | (27.23%) |
| Mar 2026 | $1.91 | 29.05% |
| Dec 2025 | $1.48 | (27.45%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UTHR United Therapeutics Corporation compare | $26.50 |
| NBIX Neurocrine Biosciences, Inc. | $6.74 |
| ZTS Zoetis Inc. compare | $6.07 |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $1.30 |
| HLN Haleon PLC Sponsored ADR compare | $0.45 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ALKS Alkermes plc compare | −$0.01 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| VTRS Viatris Inc. compare | −$0.53 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on NBIX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement